As of 2025-06-08, the Intrinsic Value of InVivo Therapeutics Holdings Corp (NVIV) is -42.09 USD. This NVIV valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.32 USD, the upside of InVivo Therapeutics Holdings Corp is -13,225.55%.
Based on its market price of 0.32 USD and our intrinsic valuation, InVivo Therapeutics Holdings Corp (NVIV) is overvalued by 13,225.55%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -42.09 - -42.09 | -42.09 | -13,225.55% |
| P/E | (98.76) - (109.38) | (102.98) | -32209.4% |
| DDM - Stable | (32.25) - (301.02) | (166.64) | -52060.9% |
| DDM - Multi | (35.01) - (259.85) | (62.21) | -19496.9% |
| Market Cap (mil) | 1.00 |
| Beta | 1.99 |
| Outstanding shares (mil) | 3.11 |
| Enterprise Value (mil) | -7.58 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.70% |
| Cost of Debt | 5.00% |
| WACC | 5.69% |